Back to Journals » OncoTargets and Therapy » Volume 5

Targeted agents for the treatment of metastatic melanoma

Authors Monzon, Dancey J

Received 29 November 2011

Accepted for publication 15 January 2012

Published 5 March 2012 Volume 2012:5 Pages 31—46


Review by Single anonymous peer review

Peer reviewer comments 3

Jose G Monzon, Janet Dancey

NCIC Clinical Trials Group, Kingston, Ontario, Canada

Abstract: In the last year, the armamentarium of melanoma therapeutics has radically changed. Recent discoveries in melanoma biology and immunology have led to novel therapeutics targeting known oncogenes and immunotherapeutic antibodies. Phase III clinical trials of these agents have reported measurable and meaningful benefits to patients with metastatic disease. In this article, we review recent findings and discuss their significance in melanoma therapy. As our understanding of melanoma biology grows, this initial therapeutic success may be enhanced through the use of molecular markers to select patients, and new targeted immunotherapies in sequential or combination drug regimens.

Keywords: metastatic melanoma, ipilimumab, vemurafenib, antitumor

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.